Business Wire

HCL-TECHNOLOGIES

27.2.2020 17:17:12 CET | Business Wire | Press release

Share
HCL Foundation Announces Winners of Fifth Edition of HCL Grant

HCL Foundation (HCLF), the Corporate Social Responsibility (CSR) arm of HCL Technologies, today announced the recipients of the fifth edition of HCL Grant in the presence of Padma Bhushan, Mr. Kapil Dev, a legend in the global world of cricket and former captain of the Indian Cricket team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200227005709/en/

HCL Grant is one of the biggest and most coveted institutionalized CSR grants in India that aims to recognize the rise of the Fifth Estate - the Non-Governmental Organizations (NGOs).

The evening was also graced by Mr. Shiv Nadar, Founder & Chairman, HCL, Ms. Roshni Nadar Malhotra, Vice Chairperson of HCL Technologies and the Chairperson of its CSR committee, and Mr. Prateek Aggarwal, Chief Financial Officer, HCL Technologies along with senior dignitaries, officials, NGO-partners and HCL leadership.

HCL Grant 2020 witnessed three NGOs across the categories of Education, Healthcare and Environment receiving a grant of ₹5 crores each. The remaining six finalists across the three categories also received ₹25 lakhs each, taking the overall Grant to ₹16.5 crore.

The finalists and the winners were selected by an eminent jury, which was chaired by Ms. Robin Abrams, Member of the Board, HCL Technologies.

Recipients of HCL Grant 2020:

  • Environment- The 2020 HCL Grant winner in this category is Under The Mango Tree Society.
    Project Location: 4 districts (Gujarat, Maharashtra and Madhya Pradesh)
  • Healthcare- The 2020 HCL Grant winner in this category is Operation ASHA.
    Project Location: Kullu (Himachal Pradesh)
  • Education- The 2020 HCL Grant winner in this category is Bal Raksha Bharat.
    Project Location: Leh (Ladakh) and Budgam (J&K)

“It is extremely important to bring equal opportunities to people coming from every strata of the society. Health, Education and Environment are one of the most important pillars towards India’s development goals and I am highly impressed with the kind of impact these NGOs are bringing in the rural communities. Also, the robustness of the identification process is something I have not witnessed before. I congratulate both HCL as well the winners and finalists for the phenomenal work they are doing in their respective fields,” Mr. Kapil Dev said while addressing the audience at the event.

Excluding the current grant, HCL Grant has already disbursed ₹51.5 crores (US$ 7.4Mn) to benefit nearly 500,000 people and its supported projects aim to cover over a million people spread across 7,500 villages across 13 States and one Union Territory in the country.

“HCL Foundation is our long-term commitment for social development and today it has improved over 1.5 million lives across our country. Our collaborative model allows us to support communities with critical concerns needing immediate attention and HCL Grant is a prime example of the same. I am proud to say that today the improvements we have been able to drive together with the HCL Grant partner NGOs is not just in terms of immediate impact on beneficiary lives, but also about ensuring long-term sustainable change by influencing state and government policies,” said Ms. Roshni Nadar Malhotra, Vice-Chairperson, HCL Technologies and Chairperson, CSR Committee, HCL Technologies.

Ms. Nidhi Pundhir, Director HCL Foundation, said, “This is a very special year for us as we complete half a decade of empowering the NGOs that are committed to ushering change. This annual HCL Grant event is a culmination of our year-long efforts to identify partners who have the potential to achieve the maximum impact through their social development projects.. We are truly honored to have received applications from all parts of the country and my heartiest congratulations to the winning NGOs for giving us the opportunity to partner with them and support ideas for impactful positive change.”

HCL Foundation also released the compendium of the previous year’s finalists and winning NGOs, named “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education”.

For more information please visit www.hclfoundation.org/hcl-grant .

Link:

ClickThru

Social Media:

https://www.facebook.com/HCLTechnologies/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye